Shaokun Chuai

3.0k total citations · 1 hit paper
29 papers, 1.8k citations indexed

About

Shaokun Chuai is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Shaokun Chuai has authored 29 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Shaokun Chuai's work include Lung Cancer Treatments and Mutations (10 papers), Ovarian cancer diagnosis and treatment (5 papers) and BRCA gene mutations in cancer (4 papers). Shaokun Chuai is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Ovarian cancer diagnosis and treatment (5 papers) and BRCA gene mutations in cancer (4 papers). Shaokun Chuai collaborates with scholars based in United States, China and Canada. Shaokun Chuai's co-authors include James D. Lewis, Jonas H. Ellenberg, Lisa Nessel, Gary R. Lichtenstein, Faten Aberra, Nicole Ishill, Ashok R. Shaha, Jatin P. Shah, Diane L. Carlson and Ronald Ghossein and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Shaokun Chuai

29 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis

2008 678 citations James D. Lewis, Shaokun Chuai et al. Inflammatory Bowel Diseases profile →

Peers

Countries citing papers authored by Shaokun Chuai

Since Specialization

Citations

This map shows the geographic impact of Shaokun Chuai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shaokun Chuai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shaokun Chuai more than expected).

Fields of papers citing papers by Shaokun Chuai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shaokun Chuai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shaokun Chuai. The network helps show where Shaokun Chuai may publish in the future.

Co-authorship network of co-authors of Shaokun Chuai

This figure shows the co-authorship network connecting the top 25 collaborators of Shaokun Chuai. A scholar is included among the top collaborators of Shaokun Chuai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shaokun Chuai. Shaokun Chuai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer 2021 ·Thoracic Cancer ·(unknown), Yu Chen, Zhi Xie, Jie Jiang, (unknown), Wei‐Bang Guo, Wenqing Yan, Zhiyi Lv, (unknown), (unknown), Fangping Xu, Jin‐Ji Yang, Xue‐Ning Yang, Qing Zhou, (unknown), Zhou Zhang, Shaokun Chuai, Henghui Zhang, Yi‐Long Wu, Xu‐Chao Zhang	9
2	Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial 2019 ·EBioMedicine ·Yichen Zhang, Zhihong Chen, Xu‐Chao Zhang, Chong‐Rui Xu, Hong‐Hong Yan, Zhi Xie, Shaokun Chuai, Junyi Ye, Han Han‐Zhang, Zhou Zhang, Xiaoyan Bai, Jian Su, Bin Gan, Jin‐Ji Yang, Wenfeng Li, Wei Tang, Feng Luo, Xiao Xu, Yi‐Long Wu, Qing Zhou	35
3	First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non–Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance 2018 ·Journal of Thoracic Oncology ·Yuxiang Ma, Xin Xiao Zheng, Hongyun Zhao, Wenfeng Fang, Yang Zhang, (unknown), Lu Wang, Weicong Wang, Ji Jiang, Shaokun Chuai, Zhou Zhang, Wanhong Xu, Xiao Xu, Pei Hu, Li Zhang	49
4	Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report 2016 ·BMC Cancer ·Wenhua Liang, Qihua He, Ying Chen, Shaokun Chuai, Weiqiang Yin, Wei Wang, Guilin Peng, Caicun Zhou, Jianxing He	35
5	Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing 2015 ·Journal of genetics and genomics ·Lulu Yang, Xu‐Chao Zhang, Shaokun Chuai, Zhihong Chen, (unknown), Wei‐Bang Guo, Shiliang Chen, Yuanyuan Lei, Longhua Guo, Lan-ying Gou, Huiwen Sun, Qi Zhang, Jin‐Ji Yang, Hai‐Yan Tu, Jian Su, Yi‐Long Wu	2
6	Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer 2015 ·Scientific Reports ·Yang Yu, Li Dong, Dapeng Li, Shaokun Chuai, Zhigang Wu, Xiangqian Zheng, Yanan Cheng, Lei Han, Jinpu Yu, Ming Gao	22
7	Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial 2008 ·Gastroenterology ·James D. Lewis, Gary R. Lichtenstein, Julius J. Deren, Bruce E. Sands, Stephen B. Hanauer, Jeffrey A. Katz, Bret A. Lashner, Daniel H. Present, Shaokun Chuai, Jonas H. Ellenberg, Lisa Nessel, Gary D. Wu	180
8	Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis breakdown → 2008 ·Inflammatory Bowel Diseases ·James D. Lewis, Shaokun Chuai, Lisa Nessel, Gary R. Lichtenstein, Faten Aberra, Jonas H. Ellenberg	678
9	Comparison of matrix metalloproteinase 9 and brain natriuretic peptide as clinical biomarkers in chronic heart failure 2008 ·American Heart Journal ·Esther Vorovich, Shaokun Chuai, Mingyao Li, (unknown), (unknown), (unknown), Muredach P. Reilly, Thomas P. Cappola	21
10	Epidermal Growth Factor Receptor Signaling in Adenocarcinomas With Bronchioloalveolar Components 2007 ·The Annals of Thoracic Surgery ·Inderpal S. Sarkaria, Maureen F. Zakowski, DuyKhanh Pham, Michael Hezel, Michael I. Ebright, Shaokun Chuai, Ennapadam Venkatraman, Mark G. Kris, Valerie W. Rusch, Bhuvanesh Singh	6
11	Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma 2007 ·BMC Medical Genetics ·Javier Cotignola, Boris Reva, Nandita Mitra, Nicole Ishill, Shaokun Chuai, Ami B. Patel, (unknown), (unknown), Daniel G. Coit, Klaus J. Busam, Allan C. Halpern, Alan N. Houghton, Chris Sander, Marianne Berwick, Irene Orlow	51
12	Patients with a major depressive episode responding to treatment with repetitive transcranial magnetic stimulation (rTMS) are resistant to the effects of rapid tryptophan depletion 2006 ·Depression and Anxiety ·John P. O’Reardon, Pilar Cristancho, (unknown), (unknown), Shaokun Chuai, (unknown)	28
13	Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important? 2006 ·International Journal of Gynecological Cancer ·Jakob Dupont, Carol Aghajanian, (unknown), Meghan Lovegren, Shaokun Chuai, E. S. Venkatraman, Martee L. Hensley, Sibyl Anderson, David R. Spriggs, Paul Sabbatini	6
14	p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas 2006 ·International Journal of Gynecological Cancer ·Sibyl Anderson, Daisuke Nonaka, Shaokun Chuai, Adam B. Olshen, D.S. Chi, Paul Sabbatini, Robert A. Soslow	29
15	Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis 2006 ·Cancer ·David Hiltzik, Diane L. Carlson, R. Michael Tuttle, Shaokun Chuai, Nicole Ishill, Ashok R. Shaha, Jatin P. Shah, (unknown), Ronald Ghossein	226
16	Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma 2005 ·Gynecologic Oncology ·Aliza Leiser, Sibyl Anderson, Daisuke Nonaka, Shaokun Chuai, Adam B. Olshen, S. Dennis, Robert A. Soslow	44
17	Localization of breast cancer susceptibility loci by genome‐wide SNP linkage disequilibrium mapping 2005 ·Genetic Epidemiology ·Nathan A. Ellis, Tomas Kirchhoff, Nandita Mitra, (unknown), Shaokun Chuai, Helen J. Huang, Khédoudja Nafa, Larry Norton, Susan L. Neuhausen, Derek Gordon, Jeffery P. Struewing, Steven A. Narod, Kenneth Offit	11
18	Paclitaxel and carboplatin (TP) for treatment of advanced or recurrent endometrial cancer: A retrospective study 2005 ·Journal of Clinical Oncology ·Mika A. Sovak, Shaokun Chuai, Sibyl Anderson, R. Barakat, Jakob Dupont, Martee L. Hensley, Paul Sabbatini, David R. Spriggs, Carol Aghajanian	3
19	Localization of Cancer Susceptibility Genes by Genome-wide Single-Nucleotide Polymorphism Linkage-Disequilibrium Mapping 2004 ·Cancer Research ·Nandita Mitra, (unknown), Alex Smith, Shaokun Chuai, Tomas Kirchhoff, Paolo Peterlongo, Khédoudja Nafa, Michael Phillips, Kenneth Offit, Nathan A. Ellis	11
20	SCCRO Expression Correlates With Invasive Progression in Bronchioloalveolar Carcinoma 2004 ·The Annals of Thoracic Surgery ·Inderpal S. Sarkaria, DuyKhanh Pham, Ronald Ghossein, Simon G. Talbot, Michael Hezel, Mária Dudás, Michael I. Ebright, Shaokun Chuai, Natalie Memoli, Ennapadam Venkatraman, Vincent A. Miller, Mark G. Kris, Maureen F. Zakowski, Valerie W. Rusch, Bhuvanesh Singh	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact